ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
ImmuCell announced preliminary unaudited Q3 2026 sales of $8.0 million, up 46% year-over-year, with nine-month sales of $25.6 million, up 27.8%. Growth was broad-based: Tri-Shield rose 51%, Dual-Force 36%, and the new functional feed line 37%, aided by depressed Q3 2025 comparisons after heavy distributor purchases in Q2 2025.
Key figures
- Revenue
- $8.0 million
- Revenue Yoy
- 46.0%
- Domestic sales
- $6.9 million
- Nine month sales
- $25.6 million
- Dual force growth
- 36%
- Tri shield growth
- 51%
- Domestic sales yoy
- 29.2%
- Nine month sales yoy
- 27.8%
- Functional feed growth
- 37%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.